Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →There is no single marking route for every UK market. In Great Britain (GB), manufacturers can use the UKCA route or, if a device qualifies, place a CE-marked IVD on the market under a time-limited transition arrangement. Northern Ireland (NI) follows the EU IVDR framework and requires CE marking. In every case, the right route depends on the destination, the device’s intended purpose and classification, and its conformity-assessment and certificate status.
Start by separating Great Britain, Northern Ireland and the EU
GB means England, Scotland and Wales. NI is a separate regulatory destination for IVDs, even though it is part of the UK. The MHRA’s guidance distinguishes these markets: GB uses the Medical Devices Regulations 2002 (UK MDR 2002), as amended, while the EU In Vitro Diagnostic Medical Devices Regulation (IVDR) applies in NI and the EU.
| Market | Main framework and route | Marking | Key point for manufacturers |
|---|---|---|---|
| Great Britain | UK MDR 2002, as amended; eligible CE-marked devices may also be accepted during transition | UKCA for the UKCA route, or qualifying CE marking under the applicable transition | Register the IVD with the MHRA before placing it on the GB market. |
| Northern Ireland | EU IVDR | CE; CE plus UK(NI) where a UK body conducts the relevant mandatory third-party assessment | UKCA alone is not accepted. CE plus UK(NI) is not accepted in the EU. |
| European Union | EU IVDR | CE | Use an EU-recognised notified body where third-party assessment is mandatory. |
The MHRA overview, “Regulating medical devices in the UK,” and its NI guidance, “Regulation of medical devices in Northern Ireland,” set out these market distinctions. Do not treat a GB route or registration as automatically covering NI or the EU.
Determine the device’s route before choosing a mark
Classification and intended purpose affect the conformity-assessment route. The product’s certificate status and the legislation under which it was assessed also matter, particularly if relying on CE acceptance in GB. A mark is the outcome of the applicable conformity process; it is not a substitute for identifying that process.
#1 Best Overall
- FDA-Approved & Clinically Trusted: The only oral fluid HIV self-test capable to detect both HIV-1 and HIV-2 antibodies. The same trusted test used by healthcare providers. Approved for use in individuals 14 years of age and older
- Quick & Easy Results in 20 Minutes: Just three simple steps and 20 minutes to know your HIV status, no lab visit or waiting required. Contact the OraSure support call center for confidential expert assistance and guidance if needed. FSA/HSA Eligible
- Pain-Free Oral Swab Testing: Uses a gentle gum swab; no needles, no discomfort, and no mess. Each kit includes: 1 OraQuick test device and vial, 1 Test Stand, 1 "HIV, Testing & Me" educational booklet, 1 instructional guide
- Confidential & Convenient At-Home Testing: Perform your test anytime, anywhere, with complete privacy. No appointments, waiting rooms, or follow-up visits. Ideal for individuals seeking discreet, self-directed HIV testing
- Sustainable & Reliable: Rebranded from OraQuick In-Home HIV Test with eco-friendly packaging; same trusted accuracy and performance as before.
- Fix the destination markets. Decide whether the IVD will be placed in GB, NI, the EU, or more than one of them. Assess each destination separately.
- Document intended purpose and classification. Establish the intended purpose and applicable IVD classification under the framework relevant to each market. Do not assume that a route or class under one framework resolves the other market’s requirements.
- Identify the applicable legislation and conformity route. For GB, assess the UKCA route under UK MDR 2002 or whether the device meets the conditions for CE transition acceptance. For NI and the EU, assess the EU IVDR route.
- Check whether a third-party assessment is required. If it is, confirm the assessor is designated or recognised for the market and route concerned. For UKCA, use the appropriate UK approved-body route; for mandatory CE assessment covering NI and the EU, use an EU-recognised notified body.
- Verify certificate and transition status. Check certificate expiry, applicable transition conditions and whether the device is eligible for the relevant GB acceptance window. Do this device by device.
- Complete separate market-entry obligations. Confirm MHRA registration for GB and the operator and registration arrangements applicable in NI or the EU before placement.
The MHRA’s guidance, “Medical devices: conformity assessment and the UKCA mark,” updated 13 May 2026, describes UKCA assessment routes. This is a regulatory overview, not a determination of an individual device’s class, evidence needs or eligibility.
When UKCA applies in Great Britain
The UKCA mark is available for medical devices, including IVDs, placed on the GB market under UK MDR 2002, as amended. IVDs are covered by Part IV of those regulations. The manufacturer must demonstrate conformity through the applicable assessment route and sign a declaration of conformity before applying UKCA.
Some routes may permit manufacturer self-declaration; where the route requires third-party assessment, the assessment must be carried out by an appropriate UK-designated approved body. If an approved body has participated, its identification number must appear below the UKCA mark. The required route depends on the device type and class, so a manufacturer should not infer that self-declaration is available for every IVD.
Rank #2
- Quick Results: Learn your blood type in just a couple of minutes with this easy-to-use testing kit
- Simple Interpretation: Easily understand your blood type group with clear and straightforward results
- Permanent Record: Keep as a permanent record of your blood type on the durable card for your records or safekeeping
- Reliable Accuracy: Offers a reliable and accurate way to learn your blood type using proven testing technology
- Convenient Home Use: Can be used conveniently at home without the need for laboratory visits
UKCA is a GB marking route. A UKCA-marked device is not accepted in NI on that mark alone. A manufacturer serving both GB and NI may therefore need distinct routes or marking arrangements, depending on the device and its assessment status.
When CE-marked IVDs can be placed on the GB market
The MHRA’s GB transition guidance gives different acceptance deadlines for devices depending on the EU legislation and transition basis. For IVDs, it states that EU IVDR-compliant devices may be placed on the GB market until 30 June 2030. EU IVDD IVDs may be placed until the sooner of the relevant certificate’s expiry or 30 June 2030, where the transition provisions apply.
| Device basis | GB acceptance stated in MHRA guidance | Qualification |
|---|---|---|
| EU IVDR-compliant IVD | Until 30 June 2030 | Acceptance is subject to the applicable conditions; it is not a blanket extension for every device. |
| EU IVDD IVD | Until the sooner of certificate expiry or 30 June 2030 | Only where the relevant transition provisions apply. |
| EU MDD- or AIMDD-compliant general device | Until the sooner of certificate expiry or 30 June 2028 | This is a general-device provision, not an IVD deadline. |
The IVDD and IVDR dates are not interchangeable. The guidance also identifies conditions and exclusions, including considerations for legacy self-declared devices and whether notified-body assessment is required under the old and new legislation. Confirm that the particular device and certificate qualify, that the relevant transition conditions have been met, and that the CE-marked device continues to meet the applicable EU legislation. Do not treat the dates as a general permission to sell any CE-marked IVD in GB.
Rank #3
- BD Veritor System offers test assays that can be used to process samples provided to the lab in an appropriate transport medium
- The first CLIA-waived Digital Immunoassay (DIA), a new category of diagnostic tests where the assay and instrument work together to combine advances in detection particles, optical image recognition and interpretation algorithms to improve accuracy
- Advanced Particle Technology enhances sensitivity by using a proprietary process to produce highly stable modified colloidal metal particles, helping improve test performance
MHRA registration and the UK responsible person
MHRA registration and conformity marking are separate obligations. The MHRA says all devices, including IVDs, custom-made devices, and systems or procedure packs, must be registered with it before placement on the GB market. Registration does not itself demonstrate that a device conforms to the applicable requirements.
A manufacturer based outside the UK must appoint one UK responsible person for all its devices. The responsible person carries out specified tasks on the manufacturer’s behalf, including registration. Manufacturers should use the current MHRA registration guidance to confirm the information required, timing, fees and any device-specific exceptions; those details can depend on the particular circumstances.
NI registration arrangements are not identical to the GB rule. The MHRA’s NI guidance has described registration for certain devices until 27 May 2026, a date that has passed. Because the applicable obligation varies by device and operator, manufacturers should consult the current detailed MHRA registration guidance before placing an IVD on the NI market rather than infer a post-deadline rule from that earlier date.
Rank #4
- FAST & EASY RESULTS IN 1 MINUTE – Simple at-home testing with clear results in as little as 60 seconds. No lab visits, no appointments, no waiting.
- PRIVATE & CONFIDENTIAL AT-HOME TESTING – Test in the comfort of your home with privacy and control from start to finish.
- OVER 99% ACCURATE - Clinically proven to deliver highly accurate results, giving you confidence in your test outcome.
- MORE ACCURATE THAN ORAL TESTS - Designed to provide greater confidence and clarity compared to oral fluid HIV tests.
- SATISFACTION GUARANTEED - If you experience any issues with your test, contact INSTI directly and we will resolve it quickly.
CE marking and UK(NI) for Northern Ireland and the EU
The EU IVDR has applied in NI since 26 May 2022, and CE marking is required there. If a UK-based body carries out mandatory third-party conformity assessment for the NI route, the device must bear CE plus UK(NI). UK(NI) is not used on its own, and CE plus UK(NI) is not accepted for placing the device on the EU market.
For a CE route intended to cover both NI and the EU, any mandatory third-party assessment must be performed by an EU-recognised notified body. The EU no longer recognises UK notified bodies for that purpose. Before contracting, check the body’s current designation and scope: recognition and scope are relevant to the assessment being performed.
The MHRA also identifies a separate supply-disruption notification duty under Article 10a for NI-based manufacturers and manufacturers whose authorised representative is based in NI. It applies where an anticipated interruption or discontinuation could foreseeably create serious harm or a risk of serious harm. Where it applies, notification must be made at least six months in advance except in exceptional circumstances, and relevant direct customers and healthcare operators must also be notified. Assess applicability for the specific manufacturer and product.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Best Value
- Tests for 5 STDs: An easy-to-use 5-Panel STD test with simple, fast, and private results. Simple HealthKit's 5-Panel STD Test screens for 5 STDs / STIs: Chlamydia, Gonorrhea, Trichomoniasis, HCV & Syphilis.
- Fast, Simple, Private: Getting tested has never been easier. Collect a urine & blood sample from the privacy of your home and send it to our lab for testing. Once the sample is received by our lab, your online results are typically available within 3 - 5 days.
- Free Follow-Up Care: Lab processing is included with your test purchase. If you receive a positive or abnormal test result, follow-up care is included. No extra charge. No hidden fees. It's that simple.
- Physician Approved, HSA / FSA Eligible, Test Intended for 18+ Only: Not Available in NY. Lab is CLIA Certified and CAP Accredited. Results delivered through a HIPAA-compliant portal.
- Fast, Simple, Private: Getting tested has never been easier. Collect a urine & blood sample from home and send it to our lab for testing. Once the sample is received by our lab, your online results are typically available within 3 - 5 days.
Plan for post-market surveillance and vigilance
Great Britain
From 16 June 2025, strengthened GB post-market surveillance (PMS) measures apply. The MHRA says these requirements extend to CE-marked devices placed on the GB market under transition provisions as well as devices on the domestic route. Manufacturers must maintain a system to gather and analyse information about device quality, performance and safety over its lifetime, record conclusions and take appropriate action. Specified incidents must be reported to the MHRA, with safety action taken where required.
Northern Ireland and the EU
EU PMS and vigilance requirements apply in NI and the EU. For NI, the MHRA identifies the MORE portal for manufacturer adverse-incident reports and the Yellow Card scheme for reports from the public and healthcare professionals. Confirm the current reporting channel and deadline for the particular incident type; the applicable route and timing should not be assumed to be the same across markets.
Make the market decision device by device
For each IVD, keep a market-entry record that identifies the intended purpose and classification, the legislation and conformity route, whether third-party assessment is required, the assessor’s relevant designation, certificate validity and transition eligibility, marking, registration and responsible-person arrangements, and post-market responsibilities. The decision should be tied to the device and destination rather than copied from another product in the portfolio.
The MHRA’s official guidance pages are live and may change. The relevant references are “Regulating medical devices in the UK,” “Medical devices: conformity assessment and the UKCA mark” (updated 13 May 2026), “Regulation of medical devices in Northern Ireland” (updated 11 June 2026), and “Approved bodies for medical devices.” For a placement decision, check the current guidance and the product-specific facts, especially classification, certificate status, transition eligibility and NI registration.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
